Literature DB >> 6722790

Biotransformations of daunorubicin aglycones by rat liver microsomes.

H S Schwartz, B Paul.   

Abstract

Daunorubicin is biotransformed anaerobically by rat liver microsomes with a reduced nicotinamide adenine dinucleotide phosphate-generating system to form a series of aglycones. The first reaction, reductive cleavage of daunosamine (at C-7 in ring A) to form the 7- deoxyaglycone , is followed by reduction of the C-13 keto group. The 7- hydroxyaglycone may also form by hydrolytic cleavage of the amino sugar followed then by the same C-13 keto reduction. These reactions are not inhibited by beta- diethylaminoethyldiphenylpropyl acetate, whereas subsequent reactions in the D ring of the aglycones can be completely blocked by this cytochrome P-450 inhibitor: reductive and hydrolytic cleavage of the C-4 methoxy group. Thus, five reactions at three sites are described and theoretical pathways are proposed for the expected 12 aglycones from daunorubicin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6722790

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Aspects of the chemical stability of doxorubicin and seven other anthracyclines in acidic solution.

Authors:  J H Beijnen; G Wiese; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1985-06-21

Review 2.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

3.  Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats.

Authors:  K H Cowan; G Batist; A Tulpule; B K Sinha; C E Myers
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

Review 4.  A chemical perspective on the anthracycline antitumor antibiotics.

Authors:  B R Abdella; J Fisher
Journal:  Environ Health Perspect       Date:  1985-12       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.